The analysis of tumors across 22 tumor types including melanoma from 4 KEYNOTE clinical trials showed that TMB and inflammatory biomarkers (T cell-inflamed GEP and PD-L1 expression) can jointly stratify human cancers into groups with different clinical responses to pembrolizumab monotherapy. Here, CD274 is linked to neoplasm.